highly bioavailable oral formulation renders voriconazole
clinical pharmacokinetic study summary
human liver microsomes
undergoing phase iii clinical trials
vitro human liver microsomal study documented
filamentous fungi including aspergillus species
inhibit cytochrome p450 3a4/5
vitro study qualitatively predicted
placebo-controlled pharmacokinetic study
transplant patients receiving voriconazole
human liver microsomes
